Contemporary role of modern brachytherapy techniques in the management of malignant thoracic tumors.

W. Harms, H. Becker, R. Krempien, M. Wannenmacher
{"title":"Contemporary role of modern brachytherapy techniques in the management of malignant thoracic tumors.","authors":"W. Harms, H. Becker, R. Krempien, M. Wannenmacher","doi":"10.1002/SSU.1017","DOIUrl":null,"url":null,"abstract":"Sole brachytherapy for carcinoma of the lung is most often performed using high-dose-rate (HDR) remote afterloading equipment, which delivers the treatment within the tracheobronchial tree in an outpatient setting. It provides excellent, rapid palliation in advanced stages, and can also be used selectively for curative intent in early stages. In better-performance patients, fractionated external beam radiation therapy (EBRT) is preferred to brachytherapy as an initial treatment because it appears to provide a modest gain in survival, and more sustained palliation. In patients with centrally located tumors and limited extent of disease, the combination of external and endoluminal irradiation enables curative treatment options. Intraoperative brachytherapy may complement standard adjuvant treatment in incompletely resected, unresectable, or medically inoperable patients, and has the potential to improve local control in selected cases. Due to the rarity of the disease, the role of endoluminal brachytherapy in the treatment regimen of tracheal neoplasms is not yet clearly defined. The risk of fatal bleeding after endoluminal brachytherapy appears to be correlated with tumor localization and fraction size, but in the majority of cases fatal bleeds are caused by progression of local disease. The use of a distanceable applicator provides a central positioning of the source, prevents the delivery of high-contact doses to the mucosa, and may reduce toxicity. The standard technique for interstitial brachytherapy after breast-conserving surgery and adjuvant EBRT is the use of low-dose-rate (LDR) brachytherapy, but it may also be applied by means of pulsed-dose-rate (PDR) or HDR techniques. Prospective trials comparing different boost techniques and indications are needed to define more precisely the subgroup of patients who are most suitable for interstitial brachytherapy. Reirradiation of chest wall local recurrences using brachytherapy molds is effective and provides a high local control rate with acceptable toxicity.","PeriodicalId":77390,"journal":{"name":"Seminars in surgical oncology","volume":"20 1","pages":"57-65"},"PeriodicalIF":0.0000,"publicationDate":"2001-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"14","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Seminars in surgical oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1002/SSU.1017","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 14

Abstract

Sole brachytherapy for carcinoma of the lung is most often performed using high-dose-rate (HDR) remote afterloading equipment, which delivers the treatment within the tracheobronchial tree in an outpatient setting. It provides excellent, rapid palliation in advanced stages, and can also be used selectively for curative intent in early stages. In better-performance patients, fractionated external beam radiation therapy (EBRT) is preferred to brachytherapy as an initial treatment because it appears to provide a modest gain in survival, and more sustained palliation. In patients with centrally located tumors and limited extent of disease, the combination of external and endoluminal irradiation enables curative treatment options. Intraoperative brachytherapy may complement standard adjuvant treatment in incompletely resected, unresectable, or medically inoperable patients, and has the potential to improve local control in selected cases. Due to the rarity of the disease, the role of endoluminal brachytherapy in the treatment regimen of tracheal neoplasms is not yet clearly defined. The risk of fatal bleeding after endoluminal brachytherapy appears to be correlated with tumor localization and fraction size, but in the majority of cases fatal bleeds are caused by progression of local disease. The use of a distanceable applicator provides a central positioning of the source, prevents the delivery of high-contact doses to the mucosa, and may reduce toxicity. The standard technique for interstitial brachytherapy after breast-conserving surgery and adjuvant EBRT is the use of low-dose-rate (LDR) brachytherapy, but it may also be applied by means of pulsed-dose-rate (PDR) or HDR techniques. Prospective trials comparing different boost techniques and indications are needed to define more precisely the subgroup of patients who are most suitable for interstitial brachytherapy. Reirradiation of chest wall local recurrences using brachytherapy molds is effective and provides a high local control rate with acceptable toxicity.
现代近距离放射治疗技术在胸部恶性肿瘤治疗中的当代作用。
肺癌的单独近距离放射治疗最常使用高剂量率(HDR)远程后负荷设备,在门诊环境中在气管支气管树内进行治疗。它在晚期提供了极好的、快速的缓解,也可以选择性地用于早期的治疗目的。在表现较好的患者中,分次外束放射治疗(EBRT)优先于近距离放射治疗作为初始治疗,因为它似乎提供了适度的生存期增加,并且更持久的缓解。对于位于中心位置的肿瘤和疾病范围有限的患者,外部和腔内照射相结合可以提供根治性治疗选择。术中近距离放疗可对未完全切除、不可切除或医学上不能手术的患者进行标准辅助治疗的补充,并有可能在选定的病例中改善局部控制。由于这种疾病的罕见性,腔内近距离放射治疗在气管肿瘤治疗方案中的作用尚未明确界定。腔内近距离放射治疗后致死性出血的风险似乎与肿瘤的定位和碎片大小有关,但在大多数情况下,致死性出血是由局部疾病的进展引起的。使用距离较远的涂药器可使药源处于中心位置,防止高接触剂量向粘膜输送,并可降低毒性。保乳手术和辅助EBRT后间质性近距离放疗的标准技术是使用低剂量率(LDR)近距离放疗,但也可以采用脉冲剂量率(PDR)或HDR技术。需要前瞻性试验比较不同的增强技术和适应症,以更准确地确定最适合间质性近距离放疗的患者亚组。使用近距离治疗模具对胸壁局部复发进行再照射是有效的,并提供了高的局部控制率和可接受的毒性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信